| 李哲成,陈朝霞,吴昭颐,等.聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎病人肝功能及肝纤维化的影响[J].安徽医药,2017,21(8):1490-1493. |
| 聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎病人肝功能及肝纤维化的影响 |
| Effect of pegylated interferon α-2a combined with entecavir on hepatic function and hepatic fibrosis in patients with chronic hepatitis B |
| 投稿时间：2016-08-04 |
| DOI： |
| 中文关键词: 恩替卡韦 聚乙二醇干扰素α-2a 慢性乙型肝炎 肝纤维化 |
| 英文关键词: Entecavir Pegylated interferon α-2a Chronic hepatitis B Liver fibrosis |
| 基金项目: |
|
| 摘要点击次数: 2736 |
| 全文下载次数: 659 |
| 中文摘要: |
| 目的 探讨聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎病人肝功能及肝纤维化的影响。方法 将70例慢性乙型肝炎病人分为观察组和对照组,各35例。全部病人给予常规综合治疗,对照组采用恩替卡韦治疗,观察组采用聚乙二醇干扰素α-2a联合恩替卡韦治疗,比较两组病人肝功能及肝纤维化程度。结果 观察组总有效为88.57%,对照组为62.86%,两组比较差异有统计学意义(χ2=6.293,P<0.05)；两组治疗后总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GGT)均显著降低(P<0.05)；观察组治疗后AST、ALT、TBil、GGT显著低于对照组治疗后,差异有统计学意义(t=5.410、7.084、7.414、2.460,P<0.05)；两组治疗后透明质酸酶(HA)、Ⅲ型前胶原(PCⅢ)、层连黏蛋白(LN)、IV型肽原(Ⅳ-C)均显著降低(P<0.05)；观察组治疗后HA、PCⅢ、LN、Ⅳ-C显著低于对照组治疗后,差异有统计学意义(t=14.194、3.666、3.896、4.362,P<0.05)；两组均未出现明显的全身或局部不良反应。结论 聚乙二醇干扰素α-2a联合恩替卡韦能显著提高慢性乙型肝炎病人的肝功能,逆转肝纤维化进程。 |
| 英文摘要: |
| Objective To investigate the effects of pegylated interferon α-2a combined with entecavir on liver function and hepatic fibrosis in patients with chronic hepatitis B. Methods 70 cases of chronic hepatitis Bwere divided into observation group(n=35) and control group(n=35).All patients were treated with conventional therapy.The control group used in treatment with entecavir.The observation group were treated with pegylated interferon α-2a combined with entecavir.Liver function and liver fibrosis in two groups were compared. Results The total effective of observation group was 88.57% and the control group was 62.86%.There were statistically significant differences between the two groups(χ2=6.293,P<0.05).After treatment in the two groups of total bilirubin(TBil),alanine aminotransferase(ALT),aspartate aminotransferase(AST),valley ammonia acyl turn peptidase(GGT) were significantly decreased(P<0.05),but the observation group was significantly lower than the control group.The difference was statistically significant(t=5.410,7.084,7.414,2.460,P<0.05).After treatment,hyaluronidase(HA),type Ⅲ collagen(PCⅢ),the layer of mucin(LN) and type IV peptide(Ⅳ-C) were significantly decreased(P<0.05).And the observation group was significantly lower than the control group.The difference was statistically significant(t=14.194,3.666,3.896,4.362,P<0.05).There were no obvious systemic or local adverse reactions in the two groups. Conclusion Pegylated interferon α-2a combined with entecavir can significantly improve liver function in patients with chronic hepatitis Band reverse the process of hepatic fibrosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
